Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
Sponsor: Second Xiangya Hospital of Central South University
Summary
The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.
Official title: Circulating Tumor DNA (ctDNA) Dynamic Monitoring Plus Artificial Intelligence (AI)-Based Pathology Predict the Efficacy of Chemoimmunotherapy in Resectable Lung Squamous Cell Carcinoma (LSCC)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2023-03-23
Completion Date
2029-09-23
Last Updated
2023-03-21
Healthy Volunteers
No
Conditions
Interventions
WES and ctDNA detection
WES and ctDNA detection
Locations (1)
Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, China
Changsha, Hunan, China